KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $4.24.

  • Vertex Pharmaceuticals' EPS (Basic) rose 469.14% to $4.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $14.31, marking a year-over-year increase of 87351.35%. This contributed to the annual value of -$2.08 for FY2024, which is 11478.57% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' EPS (Basic) is $4.24, which was up 469.14% from $4.02 recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' EPS (Basic) registered a high of $4.26 during Q1 2024, and its lowest value of -$13.92 during Q2 2024.
  • In the last 5 years, Vertex Pharmaceuticals' EPS (Basic) had a median value of $3.3 in 2021 and averaged $2.36.
  • In the last 5 years, Vertex Pharmaceuticals' EPS (Basic) surged by 111923.08% in 2022 and then tumbled by 49211.27% in 2024.
  • Vertex Pharmaceuticals' EPS (Basic) (Quarter) stood at $2.99 in 2021, then increased by 6.75% to $3.19 in 2022, then increased by 17.85% to $3.76 in 2023, then decreased by 5.83% to $3.54 in 2024, then grew by 19.77% to $4.24 in 2025.
  • Its EPS (Basic) stands at $4.24 for Q3 2025, versus $4.02 for Q2 2025 and $2.52 for Q1 2025.